Clinical Trials
249 trialsTherapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Study of Canakinumab in Patients With Myelofibrosis
Icahn School of Medicine at Mount Sinai
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Icahn School of Medicine at Mount Sinai
MoTD
University of Birmingham
PACRIMYEL
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Nanfang Hospital, Southern Medical University
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
ENERGIA
University of Turin, Italy
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
SICP RCT
University of Rochester
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
AVAJAK
University Hospital, Brest
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
BMT
Massachusetts General Hospital
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Fred Hutchinson Cancer Center
GR-MPN
Azienda Ospedaliero-Universitaria di Parma
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Dana-Farber Cancer Institute
WELL-MPN
Brigham and Women's Hospital
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
M.D. Anderson Cancer Center
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
M.D. Anderson Cancer Center
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
TREATMORE
Icahn School of Medicine at Mount Sinai
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
M.D. Anderson Cancer Center